Nordic Bioscience Unveils the High-Precision nordicEndotrophin™ Test for Chronic Illness Assessment

Nordic Bioscience Launches High-Precision Endotrophin Test

Nordic Bioscience has unveiled its latest innovation, the nordicEndotrophin™, a fully automated test that exhibits exceptional precision in quantifying the intact 77-amino acid signaling hormone, Endotrophin. This advanced diagnostic tool has been validated in lab settings at Nordic Bioscience, which is accredited through CAP/CLIA standards. It is expected to significantly enhance prognostic capabilities in studies focused on fibrosis and cancer.

The introduction of nordicEndotrophin™ complements the company’s existing product lineup, including nordicPRO-C6™ and nordicPRO-C3™, both of which have received FDA and CE approvals, respectively. Together, these tests collectively provide a unique solution for assessing the fibro-inflammatory axis in various chronic conditions, such as cardiovascular diseases, metabolic disorders, and renal diseases.

Endotrophin was first identified back in 2012 as a derivative of collagen, released from collagen type VI. This collagen type plays a critical role in activating fibroblasts and the subsequent development of fibrosis across different organs. Such inflammatory processes contribute to a staggering 40% of mortality in Western countries. The condition is exacerbated by obesity, which further activates fibroblasts in vital organs like the liver, kidneys, and heart. Notably, studies indicate that patients with circulating Endotrophin levels doubled from baseline experience a 100% increase in mortality risk.

By quantifying Endotrophin levels, researchers can correlate wound healing with fibrosis progression and patient outcomes, thus promoting precision medicine approaches aimed at pharmacodynamically modulating this hazardous hormone.

While PRO-C6 serves as Nordic Bioscience's pioneering portable ELISA test measuring total collagen type VI formation, focusing on a3 chains that encapsulate 12 Von Willebrand binding domains responsible for platelet activation and wound healing, nordicEndotrophin™ specifically targets the whole intact hormone of 77 amino acids. This specificity adds another layer of risk stratification and prognostic value that augments PRO-C6's pharmacodynamic insights.

Dr. Morten Karsdal, CEO of Nordic Bioscience, noted, "Endotrophin stands out as a significant prognostic biomarker. In studies encompassing HFpEF patients, it, alongside PRO-C6, demonstrated superior performance over NT-proBNP regarding mortality and hospitalization risks. When used with PRO-C3, the quantification of this fibro-inflammatory hormone will refine patient stratification and treatment monitoring across obesity, fibrotic diseases, and autoimmune endotypes."

The high-precision sandwich test of nordicEndotrophin™ is now available through fully automated, high-throughput platforms, ensuring accurate results that expedite fibro-inflammatory profiles within drug development. Potential customers are encouraged to measure nordicPRO-C3™ and nordicPRO-C6™ concurrently with nordicEndotrophin™ to enable precise risk stratification, dose selection, patient enrichment, mechanism proof, and treatment monitoring in antifibrotic and oncological trials.

About Nordic Bioscience

Based in Herlev, Denmark, Nordic Bioscience specializes in developing biomarkers with an innovative neoepitope technology. The company blends its biomarker development expertise with preclinical and clinical research to create decision-making tools that enhance compound selection in clinical trials and deliver added value to patients within the diagnostic landscape. To learn more about Nordic Bioscience, please visit www.nordicbioscience.com.